Tevogen Bio Holdings (TVGN) Non-Current Deffered Revenue (2021 - 2023)

Tevogen Bio Holdings has reported Non-Current Deffered Revenue for 3 years, with the latest figure at $14.7 million in Q4 2023.

• For the quarter ending Q4 2023, Non-Current Deffered Revenue changed 0.0% year-over-year to $14.7 million; the trailing twelve-month figure through Dec 2023 stood at $14.7 million (changed 0.0% YoY), and the FY2023 full-year result was $14.7 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue for Q4 2023 stood at $14.7 million, roughly flat from $14.7 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $14.7 million in Q4 2021, with the low at $14.7 million in Q4 2021.
• Historically, Non-Current Deffered Revenue has averaged $14.7 million across 3 years, with a median of $14.7 million in 2021.
• The largest YoY upside for Non-Current Deffered Revenue was 0.0% in 2022 against a maximum downside of 0.0% in 2022.
• Tevogen Bio Holdings' Non-Current Deffered Revenue stood at $14.7 million in 2021, then changed by 0.0% to $14.7 million in 2022, then changed by 0.0% to $14.7 million in 2023.
• The last three Non-Current Deffered Revenue figures came in at $14.7 million (Q4 2023), $14.7 million (Q3 2023), and $14.7 million (Q2 2023), per Business Quant data.